medigraphic.com

2006, Número 3

Siguiente >>

Med Sur 2006; 13 (3)


Introducción a los marcadores tumorales séricos

Contreras CNA, Lugo ÁG, Martínez QJU

Idioma: Español
Referencias bibliográficas: 50
Paginas: 111-121
Archivo PDF: 149.15 Kb.


RESUMEN

La determinación de marcadores tumorales séricos es importante para realizar una evaluación integral de los pacientes con cáncer. No existe un marcador 100% sensible y específico. Sin embargo, son muy útiles en la detección, diagnóstico, pronóstico, valoración del tratamiento y vigilancia de los pacientes con diferentes neoplasias, ya que los niveles séricos se modifican de acuerdo al curso clínico de la enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Rivera P. Utilidad Clínica de los marcadores tumorales. Rev Mex Pat Clin 1997; 44: 245-258.

  2. Enguídanos M, Todoli J, Saro E, Salvador G, Villar J, Gómez-Biedma S, Calabuig J, Micó L. Utilidad de los marcadores tumorales en el diagnóstico de neoplasia asociada a trombosis venosa profunda idiopática. Ann Med Int 2002; 19: 561-566.

  3. Rubial A. Marcadores tumorales de secreción: situación actual. Med Clin (Barc) 2002; 118: 750-756.

  4. Gómez TF, Álvarez–Sala R. Marcadores tumorales en el cáncer de pulmón. Rev Patol Respir 2002; 5: 53-54.

  5. De la Peña J. Antígeno prostático específico. Revisión bibliográfica. Rev Sanid Milit 1996; 50: 177-184.

  6. Bergman B, Brezicka FT, Engstrom CP, Larsson S. Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer. Eur J Cancer 1993; 29: 198-202.

  7. Romero S, Fernández C, Arriero JM, Espasa A, Candela A, Martin C et al. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J 1996; 9: 17-23.

  8. Satoh H, Sumi M, Yagyu H, Ishikawa H, Suyama T, Naitoh T et al. Clinical evaluation of CYFRA 21-1 in malignant pleural fluids. Oncology 1995; 52: 211-214.

  9. Ogose A, Hotta T, Kawashima H, Hatano H, Umezu H, Inoue Y et al. Elevation of serum alkaline phosphatase in clear cell chondrosarcoma of bone. Anticancer Res 2001; 21: 649-655.

  10. Camera A, Villa MR, Rocco S, De-Novellis T, Costantini S, Pezzullo L et al. Increased CA 125 serum levels in patients with advanced acute leukemia with serosal involvement. Cancer 2000; 88: 75-78.

  11. Brawer MK. Prostate-specific antigen. Semin Surg Oncol 2000; 18: 3-9.

  12. Oberg K. State of the art and future prospects in the management of neuroendocrine tumors. Q J Nucl Med 2000; 44: 3-12.

  13. Wells SA, Franz C. Medullary carcinoma of the thyroid gland. World J Surg 2000; 24: 952-956.

  14. DiBaise JK, Donovan JP. Markedly elevated CA125 in hepatic cirrhosis: two case illustrations and review of the literature. J Clin Gastroenterol 1999; 28: 159-161.

  15. Wu JT. Review of circulating tumor markers: from enzyme, carcinoembryonic protein to oncogene and suppressor gene. Ann Clin Lab Sci 1999; 29: 106-111.

  16. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9: 67-81.

  17. Shudo R, Saito T, Takahashi K, Horita K, Waku K, Honma I et al. Giant hydronephrosis due to a ureteral stone, and elevated serum levels of CA19.9. Intern Med 1999; 38: 887-891.

  18. Deftos LJ, Abrahamsson PA. Granins and prostate cancer. Urology 1998; 51: 141-145.

  19. Hunerbein M. The value of tumor markers in colorectal cancer. Recent Results Cancer Res 1998; 14: 648-655.

  20. Ferrari L, Seregni E, Martinetti A, Van-Graafeiland B, Nerini-Molteni S, Botti C et al. Chromogranin A measurement in neuroendocrine tumors. Int J Biol Markers 1998; 13: 3-9.

  21. Hayes DF. Determination of clinical utility of tumor markers: a tumor marker utility grading system. Recent. Results. Cancer Res 1998; 152: 85.

  22. Molina R, Filella X, Jo J, Agusti C, Ballesta AM. CA125 in biological fluids. Int J Biol Markers 1998; 13: 224-230.

  23. Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat 1998; 52: 239-259.

  24. White DR, Maloney JJ III, Muss HB et al. Serum alkaline phosphatase determination: value in the staging of advanced breast cancer. JAMAL 1979; 242: 1147-1152.

  25. Berkowitz RS. Recent advances in gestational trophoblastic disease. J Reprod Med 2000; 45: 692-700.

  26. Bast RC et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883-887.

  27. Kurihara T. Determination of a normal level of serum CA125 in postmenopausal women as a tool for reproductive evaluation and postoperative surveillance of endometrial carcinoma. Gynecol Oncol 1998; 69: 192-196.

  28. De los Frailes MT, Stark S, Jaeger W, Hoerauf A, Wildt L. Purification and characterization of the CA 125 tumor-associated antigen from human ascites. Tumor Biol 1993; 14: 18-29.

  29. Imai S, Maeda H, Kiyozuka Y, Morimoto J, Haga S, Noda T, Hiroishi S, Hilgers J. Monoclonal antibodies against CA125-bearing antigenic molecule fragments; reactivity with mucinous ovarian tumours and lung cancers. Mol Cell Probes 1991; 5: 55-63.

  30. Nagata A, Hirota N, Sakai T, Fujimoto M, Komoda T. Molecular nature and possible presence of a membranous glycan-phosphatidylinositol anchor of CA125 antigen. Tumor Biol 1991; 12: 279-286.

  31. Fendrick JL, Staley KA, Gee MK, McDougald SR, Quirk JG, Jr., O’Brien TJ. Characterization of CA 125 synthesized by the human epithelial amnion WISH cell line. Tumor Biol 1993; 14: 310-318.

  32. Konishi I, Fendrick JL, Parmley TH, Quirk JG Jr., O’Brien TJ. Epidermal growth factor enhances secretion of the ovarian tumor-associated antigen CA125 from the human amnion WISH cell line. J Soc Gynecol Invest 1994; 1: 89-96.

  33. Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA. Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 1993; 39: 2509-2513.

  34. Santos-Juanes J, Bernaldo QJF, Galache OC, Sanchez RJ, Allende MT, Folgueras MV, Soto DJ. Apocrine carcinoma, adenopathies, and raised TAG-72 serum tumor marker. Dermatol Surg 2004; 30: 566-569.

  35. Vrdoljak DV, Knezevic F, Ramljak V. The relation between tumor marker Ca 15-3 and metastases in interpectoral lymph nodes in breast cancer patients. Saudi Med J 2006; 27: 460-462.

  36. Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Altorjai G, Locker GJ, Mader R, Zielinski CC, Steger GG. Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment. BMC Cancer 2006; 6: 81.

  37. Buyru N, Tigli H, Duranyildiz D, Dalay N. Molecular detection of squamous cell carcinoma antigen transcripts in peripheral blood of cancer patients. Clin Chem Lab Med 2006; 44(5): 538-41.

  38. Raspollini MR, Amunni G, Villanucci A, Castiglione F, Degl’innocenti DR, Baroni G, Paglierani M, Taddei GL. HER-2/neu and bcl-2 in Ovarian Carcinoma: Clinicopathologic, Immunohistochemical, and Molecular Study in Patients With Shorter and Longer Survival. Appl Immunohistochem Mol Morphol 2006; 14: 181-186.

  39. Pectasides D, Gaglia A, Arapantoni-Dadioti P, Bobota A, Valavanis C, Kostopoulou V, Mylonakis N, Karabelis A, Pectasides M, Economopoulos T. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res 2006; 26: 647-653.

  40. Li Y, Tang ZY, Tian B, Ye SL, Qin LX, Xue Q, Sun RX. Serum CYFRA 21-1 level reflects hepatocellular carcinoma metastasis: study in nude mice model and clinical patients. J Cancer Res Clin Oncol 2006; 132: 515-520.

  41. Uenishi T, Yamazaki O, Yamamoto T, Hirohashi K, Tanaka H, Tanaka S, Hai S, Ono K, Kubo S. Clinical significance of serum cytokeratin-19 fragment (CYFRA 21-1) in hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2006; 13: 239-244.

  42. Gopan T, Remer E, Hamrahian AH. Evaluating and managing adrenal incidentalomas. Cleve Clin J Med 2006; 73: 561-568.

  43. Lewis S, Dirnhuber M, Soar J. An unusual presentation of a pheochromocytoma. J Cardiothorac Vasc Anesth 2006; 20: 390-393.

  44. Darvishian F, Ginsberg MS, Klimstra DS, Brogi E. Carcinoid tumorlets simulate pulmonary metastases in women with breast cancer. Hum Pathol 2006; 37: 839-844.

  45. Raut CP, Kulke MH, Glickman JN, Swanson RS, Ashley SW. Carcinoid tumors. Curr Probl Surg 2006; 43: 391-450.

  46. Biliotti G, Martini F, Vaggelli L, Messerini L, Colagrande S, Pupi A, Seghi P. Multiple effects of somatostatin analogs verified in three cases of metastasized neuroendocrine tumors of the gastroenteropancreatic system. Tumori 2006; 92: 170-174.

  47. Rizk MK, El-Nawawy A, Abdel-Kareem E, Amer ES, El-Gezairy D, El-Shafei AZ. Serum interleukins and urinary microglobulin in children with idiopathic nephrotic syndrome. East Mediterr Health J 2005; 11: 993-1002.

  48. Delbridge L. Solitary thyroid nodule: current management. ANZ J Surg 2006; 76: 381-386.

  49. Morganti S, Ceda GP, Saccani M, Milli B, Ugolotti D, Prampolini R, Maggio M, Valenti G, Ceresini G. Thyroid disease in the elderly: Sex-related differences in clinical expression. J Endocrinol Invest 2005; 28: 101-104.

  50. Bihan H, Becker KL, Snider RH, Nylen E, Vittaz L, Lauret C, Modigliani E, Moretti JL, Cohen R. Calcitonin precursor levels in human medullary thyroid carcinoma. Thyroid 2003; 13: 819-822.




2020     |     www.medigraphic.com